Illumina (NASDAQ:ILMN) Issues Earnings Results, Beats Estimates By $0.26 EPS

Key Points

• Illumina beat quarterly expectations: EPS was $1.62 versus the $1.36 consensus, while revenue reached approximately $1.17 billion, slightly above estimates.
• Management raised its 2026 outlook to $4.64–$4.66 billion in revenue and $5.40–$5.45 in EPS, supported by strong clinical sequencing demand, more than 80 NovaSeq X placements, and 14% growth in clinical consumables.
• Growth remains mixed: Margins and free cash flow improved, but research consumables declined 6%, pricing headwinds persist, and analysts maintain a consensus “Hold” rating despite emerging AI and multi-omics opportunities.

Illumina (NASDAQ:ILMN - Get Free Report) released its quarterly earnings data on Thursday. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.26, FiscalAI reports. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.

Here are the key takeaways from Illumina's conference call:

• Strong Q3 performance and raised guidance: Rest-of-world organic revenue grew approximately 5%, operating margin reached 25%, and adjusted EPS was $1.44, ahead of expectations. Illumina raised full-year 2026 revenue guidance to $4.64–$4.66 billion and EPS guidance to $5.40–$5.45.
• Clinical demand and NovaSeq X placements remain robust: The company placed more than 80 NovaSeq X instruments in Q3, with clinical sequencing consumables growing 14% year over year. Illumina said the expanding installed base should support consumables revenue for years and expects clinical consumables growth in the mid-teens for 2026.
• Research and applied sequencing consumables declined 6% in the rest of the world, although management said activity appears to be stabilizing. The NovaSeq X transition is largely complete in research markets, while clinical conversion is expected to reach roughly 80%–85% and continue creating pricing headwinds, though less so in 2027.
• Margins and cash generation improved: Q3 gross margin was 69.4% and free cash flow was $378 million. Illumina expects approximately 23.6% operating margin for full-year 2026 and plans to continue opportunistic share repurchases, with about $1.8 billion remaining under its authorization.
• AI, multi-omics, and data initiatives are emerging growth opportunities: Illumina reported growing interest in its Billion Cell Atlas and BioInsight platform, including from GSK, and expects these offerings to become more visible in the financial results around 2027. Management believes multi-omics and AI-driven biological datasets could provide upside beyond its high-single-digit long-term growth framework, though the timing and scale remain uncertain.

Illumina Stock Performance

ILMN stock traded up $1.27 during trading on Thursday, reaching $290.06. 2,024,433 shares of the company's stock were exchanged, compared to its average volume of 2,162,706. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina has a 1-year low of $94.00 and a 1-year high of $309.35. The company's fifty day moving average price is $247.14 and its 200-day moving average price is $174.99. The firm has a market cap of $43.80 billion, a PE ratio of 54.12, a P/E/G ratio of 3.82 and a beta of 1.41.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported non-GAAP earnings of $1.44 per share, exceeding analysts’ consensus by approximately 6%. GAAP net income was $220 million, while reported profitability remained solid. Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
• Positive Sentiment: Management’s full-year revenue outlook of approximately $4.65 billion at the midpoint was slightly above analyst expectations, suggesting confidence in demand and execution for the remainder of the year. Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
• Neutral Sentiment: Third-quarter revenue rose 4.2% year over year to $1.13 billion. However, market reports indicate this was below analysts’ expectations, making top-line growth the main focus of investor concern. Illumina Reports Sales Below Analyst Estimates
• Neutral Sentiment: Research reports highlighted strong long-term growth opportunities in sequencing-as-a-service, genomic screening, metagenomics, and precision medicine. These trends could support Illumina’s addressable market but do not represent new company-specific contracts or near-term revenue. Sequencer as a Service Global Market Report 2026
• Negative Sentiment: Robert W. Baird maintained a Hold rating, indicating that the earnings report did not provide enough evidence to justify a more bullish stance at current valuation levels. Robert W. Baird Remains a Hold on Illumina

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. TD Cowen raised their target price on Illumina from $210.00 to $270.00 and gave the company a "hold" rating in a research note on Tuesday, October 13th. Argus upped their price target on shares of Illumina from $180.00 to $235.00 and gave the stock a "buy" rating in a research report on Thursday, September 3rd. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a "hold" rating in a report on Wednesday, August 5th. Leerink Partners lifted their price objective on shares of Illumina from $220.00 to $300.00 and gave the company an "outperform" rating in a research report on Tuesday, September 29th. Finally, Stephens lowered shares of Illumina from an "overweight" rating to an "equal weight" rating and set a $275.00 target price for the company. in a research note on Friday, October 23rd. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $234.41.

Insider Activity at Illumina

In related news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 2,061,235 shares of company stock worth $436,356,102 over the last quarter. 2.90% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.